How much is ARS Pharmaceuticals worth in 2026?

ARS Pharmaceuticals has a current valuation of N/A based on their Later Stage VC (Series D) round and secondary market data.

How much funding has ARS Pharmaceuticals raised?

ARS Pharmaceuticals has raised N/A in total funding across 1 funding rounds.

ARS Pharmaceuticals

Pharmaceuticals

ARS Pharmaceuticals valuation and funding history | Last updated: August 31, 2021 | 1 funding rounds

Current Valuation

N/A

As of August 31, 2021

Total Funding Raised

N/A

Across 1 round

Last Round

Later Stage VC (Series D)

$55.0M

Last Funding

Aug 2021

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
August 31, 2021	Later Stage VC (Series D)	$55.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

ARS Pharmaceuticals is currently valued at N/A as of August 31, 2021.

Track ARS Pharmaceuticals Valuation Updates

Get notified when ARS Pharmaceuticals raises new funding or valuation changes

Explore More Data

Detailed analysis for ARS Pharmaceuticals

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock ARS Pharmaceuticals's valuation history, funding rounds, and growth metrics.

No credit card required

What is ARS Pharmaceuticals Worth in 2026?

ARS Pharmaceuticals is a leading private company in the Pharmaceuticals sector. Track ARS Pharmaceuticals's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How ARS Pharmaceuticals Valuation is Determined

Private company valuations like ARS Pharmaceuticals's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.